Safety, tolerability, and anti-fibrotic efficacy of the CBP/ß-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
EBioMedicine
; 80: 104069, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-35605429
Full text:
1
Collection:
01-internacional
Health context:
2_ODS3
/
3_ND
Database:
MEDLINE
Main subject:
Hepatitis C
/
Herpesvirus 1, Cercopithecine
/
Hepatitis C, Chronic
/
End Stage Liver Disease
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
EBioMedicine
Year:
2022
Document type:
Article